The company is reporting strong ORR, durability and PFS at ESMO in heavily pretreated colorectal cancer, an indication where Amgen’s Lumakras has struggled.
Mirati Therapeutics, Inc.’s adagrasib stands to reinforce its competitive positioning among KRAS G12C inhibitors with new data showing the drug’s efficacy in advanced colorectal cancer (CRC), as a monotherapy and in combination with Eli Lilly and Company’s EGFR inhibitor Erbitux (cetuximab).
Mirati announced a late-breaker presentation of data on 7 September from the Phase I/II KRYSTAL-1 clinical trial at the European...
Aside from several sizable global out-licensing deals, South Korean bioventures saw a cancellation of other alliances, updated their pipelines with losses and gains and reported clinical trial progress in the second quarter, while domestic IPO sentiment also improved.
New US approval in heart failure with preserved or mildly reduced ejection fraction should add to Kerendia’s earning power on top of chronic kidney disease indication.
The drugmaker announced positive results from two Phase III trials for the drug in narcolepsy type 1 that analysts said bode well for the OX2R agonist class as a whole.
